On May 2, 2023, the U.S. Food and Drug Administration (FDA) announced that it was taking additional steps…
On Apr. 11, 2023, a National Institutes of Health (NIH) clinical trial was stopped early because a daily…
On Feb. 9, 2023, the National Institutes of Health (NIH) announced that a new large-scale genetic analysis found…
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
On Sept. 22, 2022, the President signed into law the U.S. Food and Drug Administration (FDA) User Fee…
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Nov. 11, 2021, the University of Oxford began recruiting for a Phase I trial to test an…
On Aug. 11, 2021, the National Institutes of Health (NIH) announced that one dose of a new monoclonal…
On Aug. 11, 2021, the World Health Organization (WHO) announced the next phase in its Solidarity trial that…
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
On Jul. 29, 2021, the National Institutes of Health (NIH) announced it had launched a new online research…
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
On Jul. 26, 2021, Trevena announced that the first COVID-19 patient had been enrolled in the NIH-funded ACTIV-4…
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
On Jun. 29, 2021, Altimmune provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19….
On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…
On May 27, 2021, Innovation Pharma announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial…
On May 18, 2021, GlaxoSmithKline and Medicago reported positive interim Phase 2 clinical trial safety and immunogenicity data for…
On May 6, 2021, Trevena announced that TRV027, the Company’s novel AT1 receptor selective agonist, had been selected…
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
On Nov. 13, 2020, NeuroRx and Relief Therapeutics announced that to-date, 150 patients (out of a targeted enrollment…
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…
On Aug. 19, 2020, researchers at UT Southwestern Medical Center and Texas Health Resources announced that was the…
On Aug. 15, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to…